logo
Twitter
Discord
Email
logo
Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc.

NASDAQ•CTNM
CEO: Mr. Carmine N. Stengone MBA, MS
Sector: Healthcare
Industry: Biotechnology
Listing Date:
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Contact Information
10578 Science Center Drive, Suite 200, San Diego, CA, 92121, United States
858-333-5280
www.contineum-tx.com
Market Cap
$428.86M
P/E (TTM)
-5.6
38.2
Dividend Yield
--
52W High
$13.49
52W Low
$3.35
52W Range
83%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 4-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2022-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.45+12.50%
4-Quarter Trend

FCF

-$12.30M+96.69%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Liquidity Position Cash reserves total $182.4M; sufficient funding projected for operations spanning at least 12 months from issuance date.
R&D Investment Surge Nine months R&D expenses hit $38.8M, up $13.4M, driven by PIPE-791 clinical trial acceleration efforts.
Pipeline Advancement Milestones Advancing PIPE-307 RRMS Phase 2 trial enrollment completion; topline data anticipated in the fourth quarter of 2025.
ATM Program Proceeds Realized Raised $19.0M net proceeds during the quarter via Class A stock sales under the May 2025 ATM Sales Agreement.

Risk Factors

Widening Quarterly Net Loss Quarterly net loss widened to $(12.8M) in Q3 2025 from $(10.3M) in Q3 2024, due to increased operating expenses.
Escalating R&D Cost Structure R&D costs increased $13.4M over nine months, reflecting high external costs for advancing PIPE-791 clinical programs.
Future Financing Dependency Continued net losses necessitate external financing; assurance is lacking for securing future capital on acceptable terms if needed.
Clinical Execution Uncertainty Successful clinical trial completion and regulatory approval for drug candidates remain highly uncertain factors impacting future value.

Outlook

PIPE-791 IPF Trial Initiation Planning initiation of global Phase 2 clinical trial for wholly-owned asset PIPE-791 in IPF indication during Q4 2025.
G&A Expense Increase Expected Expect G&A expenses to increase supporting headcount growth and compliance costs associated with maintaining public company status.
Expanding Discovery Portfolio Actively pursuing preclinical and discovery-phase experiments to expand clinical portfolio targeting additional NI&I indications.
PIPE-791 Pain Trial Data Anticipate receiving topline data from the PIPE-791 chronic pain Phase 1b trial during the first half of 2026.

Peer Comparison

Revenue (TTM)

Vanda Pharmaceuticals Inc.VNDA
$212.07M
+11.1%
Editas Medicine, Inc.EDIT
$46.38M
-24.9%
AC Immune SAACIU
$5.14M
-89.3%

Gross Margin (Latest Quarter)

Editas Medicine, Inc.EDIT
100.0%
+2621.3pp
AC Immune SAACIU
100.0%
+0.0pp
Vanda Pharmaceuticals Inc.VNDA
94.7%
+0.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANNX$725.94M-4.4-92.3%11.8%
VNDA$441.45M-5.2-16.8%1.0%
CTNM$428.86M-5.6-32.3%2.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 5, 2026
|
EPS:-$0.50
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 30, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.45+12.5%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.62+77.1%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.62+87.9%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 6, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-2.18-342.2%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.40+60.0%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.35-121.6%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 16, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.33+73.7%
    N/A